FDA-approved1,2Evidence: Smaller human trialsInflammation and immune · Muscle

Zilucoplan1

Also called Zilbrysq1,2

Key takeaway

Zilucoplan is a synthetic ring-shaped (macrocyclic) peptide of 15 amino acids that blocks complement protein C5, and the active ingredient in Zilbrysq.1,2 FDA approved Zilbrysq in 2023 for generalized myasthenia gravis in adults who have antibodies against the acetylcholine receptor.1,2 In a 12-week randomized, placebo-controlled trial of 174 adults, it improved daily-function and muscle-strength scores more than placebo. The label carries a boxed warning about serious meningococcal infections.1

Zilucoplan at a glance

What it isA complement inhibitor: a 15-amino-acid synthetic macrocyclic peptide that binds complement protein C5, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Zilbrysq with an original approval date of October 17, 2023. The label has a boxed warning about serious meningococcal infections, and the drug is available only through a restricted program.1,2
Human evidenceOne 12-week multicenter, randomized, double-blind, placebo-controlled trial in 174 adults with generalized myasthenia gravis, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is zilucoplan?

Zilucoplan is a 15-amino-acid synthetic macrocyclic peptide, a peptide whose chain is closed into a ring, that the label classes as a complement inhibitor.1

In the United States it is the active ingredient of Zilbrysq, from UCB, according to Drugs@FDA.2

How does zilucoplan work?

The label states that zilucoplan binds complement protein C5 and stops it from being split, preventing formation of the terminal complement complex (C5b-9), part of the immune system’s attack machinery.1

The label states that the precise way it helps in myasthenia gravis is unknown but is presumed to involve less C5b-9 deposited where nerves meet muscle.1

What do human studies show?

The label describes a 12-week randomized, double-blind, placebo-controlled trial in 174 adults with generalized myasthenia gravis; 86 received zilucoplan and 88 placebo, most alongside their existing treatments.1

On the 24-point Myasthenia Gravis Activities of Daily Living scale, scores improved by 4.39 points with zilucoplan and 2.30 with placebo, a difference of 2.09 points, according to the label.1

Muscle-strength scores on the Quantitative Myasthenia Gravis scale also improved more with zilucoplan than with placebo, according to the label.1

What the evidence base contains

  • Controlled human trial Study 1 (NCT04115293): a 12-week multicenter, randomized, double-blind, placebo-controlled trial in 174 adults with acetylcholine-receptor-antibody-positive generalized myasthenia gravis, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is zilucoplan FDA-approved?

Yes. Drugs@FDA lists Zilbrysq, application NDA 216834, with an original approval date of October 17, 2023.2

The Zilbrysq label cited here (DailyMed SPL version 13, published February 5, 2026) states that it is indicated for generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.1

The label carries a boxed warning that, as a complement inhibitor, it increases the risk of serious and potentially fatal meningococcal infections, and states that it is available only through a restricted program (Zilbrysq REMS).1

Timeline

  1. FDA approves Zilbrysq, according to Drugs@FDA.2
  2. DailyMed publishes the Zilbrysq label version cited on this page.1

What is still unknown?

Its precise mechanism in myasthenia gravis, which the label states is unknown.1

Its effect in people without acetylcholine receptor antibodies, who are outside the approved indication in the label.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Zilucoplan: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Zilucoplan are a bounded selection, not every registration or paper about Zilucoplan. For the years before Zilucoplan was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Zilucoplan as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Zilucoplan in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Zilbrysq for generalized myasthenia gravis. A 12-week randomized, placebo-controlled trial of 174 adults described in the label found greater improvement in daily-function scores. The label has a boxed warning about serious meningococcal infections.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Zilucoplan?

FDA-approved as Zilbrysq for generalized myasthenia gravis. A 12-week randomized, placebo-controlled trial of 174 adults described in the label found greater improvement in daily-function scores. The label has a boxed warning about serious meningococcal infections.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
6
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Zilucoplan?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

25Selected dated records
27Connected citations
6Populated source years2021–2026
3/4Record lanes present

Registered human studies

Trial composition

10 of 11 selected trial records include at least one phase value; 11 of 11 include a status value in the retained structured contract.

PhasesPhase 3 7Phase 2 4Phase 1 2
Status at observationCompleted 5Recruiting 4Active, not recruiting 1Enrolling by invitation 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

11 of 11 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 6Letter 5Case Reports 2Clinical Trial, Phase II 1Multicenter Study 1Observational Study 1Research Support, Non-U.S. Gov't 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
25

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 25 dated records

Research hub

Explore the Zilucoplan evidence record

Open all 25 records →
25Dated records
3Evidence types
25Cited public sources
6Source years

Change ledger

Recently changed for Zilucoplan

Open all 25 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT04297683

PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.

PeptideScanner change date
November 15, 2026
Cited source date
July 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04382755

PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.

PeptideScanner change date
November 15, 2026
Cited source date
September 14, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04436497

PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.

PeptideScanner change date
November 15, 2026
Cited source date
July 25, 2023
Evidence lane
Clinical trials

Official-source collections

Source records for Zilucoplan

Open the full research atlas →
PubMed11

11 with attributed title, venue, publication-date, and type metadata.

  1. Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.Acta neurologica Belgica · 2026 07 17
  2. A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.JAAD case reports · 2026 07 10
  3. Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.Journal of the neurological sciences · 2026 01 23
Explore all selected literature →
ClinicalTrials.gov11

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06055959Registry update November 5, 2026 · current at observation
  2. NCT06435312Registry update October 2, 2026 · current at observation
  3. NCT07215949Registry update August 28, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span December 20, 2021 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 25

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06055959↗

    PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  2. Literature metadata

    Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.↗

    PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06435312↗

    PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07215949↗

    PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06961747↗

    PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  6. Literature metadata

    A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.↗

    PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT04297683↗

    PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  8. Literature metadata

    Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT06471361↗

    PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  10. Literature metadata

    Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan.↗

    PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ZILBRYSQ (zilucoplan) injection, solution · SPL version 13 · published 2026-02-05 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: ZILBRYSQ (zilucoplan sodium), NDA 216834 · original approval October 17, 2023 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026